{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:46Z","timestamp":1786980286877,"version":"build-2736575974"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"19-20","license":[{"start":{"date-parts":[[2013,9,6]],"date-time":"2013-09-06T00:00:00Z","timestamp":1378425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s00508-013-0417-0","type":"journal-article","created":{"date-parts":[[2013,9,5]],"date-time":"2013-09-05T02:12:30Z","timestamp":1378347150000},"page":"616-620","source":"Crossref","is-referenced-by-count":8,"title":["Intermediate to long-term follow-up results of INH chemoprophylaxis prior to anti-TNF-alpha therapy in a high-risk area for tuberculosis","Mittel- bis Langzeit-Follow-up Ergebnisse einer Chemoprophylaxe mit INH vor einer Therapie mit anti-TNF alpha in einem Hochrisikogebiet f\u00fcr Tuberkulose"],"prefix":"10.1007","volume":"125","author":[{"given":"Ozlem Kar","family":"Kurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahar","family":"Kurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahrettin","family":"Talay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncer","family":"Tug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Soy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cemal","family":"Bes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Hayran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,6]]},"reference":[{"issue":"4","key":"417_CR1","first-page":"379","volume":"79","author":"H Kaneko","year":"1999","unstructured":"Kaneko H, Yamada H, Mizuno S, et al. Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest. 1999;79(4):379\u201386.","journal-title":"Lab Invest"},{"issue":"5","key":"417_CR2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/0092-8674(89)90676-4","volume":"56","author":"V Kindler","year":"1989","unstructured":"Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell. 1989;56(5):731\u201340.","journal-title":"Cell"},{"issue":"8","key":"417_CR3","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/IAI.70.8.4591-4599.2002","volume":"70","author":"KO Kisich","year":"2002","unstructured":"Kisich KO, Higgins M, Diamond G, Heifets L. Tumor necrosis factor alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun. 2002;70(8):4591\u201399.","journal-title":"Infect Immun"},{"issue":"6","key":"417_CR4","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","volume":"43","author":"P Brassard","year":"2006","unstructured":"Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717\u201322.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"417_CR5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261\u20135.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"417_CR6","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","volume":"60","author":"F Tubach","year":"2009","unstructured":"Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884\u201394.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"417_CR7","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","volume":"8","author":"RS Wallis","year":"2008","unstructured":"Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8(10):601\u201311.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"417_CR8","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tube.2005.01.001","volume":"85","author":"TM Lasco","year":"2005","unstructured":"Lasco TM, Cassone L, Kamohara H, Yoshimura T, McMurray DN. Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis (Edinb). 2005;85(4):245\u201358.","journal-title":"Tuberculosis (Edinb)"},{"issue":"3","key":"417_CR9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148\u201355.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"417_CR10","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14656566.5.3.581","volume":"5","author":"E Toussirot","year":"2004","unstructured":"Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5(3):581\u201394.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"417_CR11","first-page":"706","volume":"34","author":"SS Seong","year":"2007","unstructured":"Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34(4):706\u201311.","journal-title":"J Rheumatol"},{"issue":"10","key":"417_CR12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/thx.2005.046797","volume":"60","author":"British Thoracic Society Standards of Care Committee","year":"2005","unstructured":"British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax. 2005;60(10):800\u20135.","journal-title":"Thorax"},{"issue":"9","key":"417_CR13","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2004.029041","volume":"64","author":"D Ponce de Le\u00f3n","year":"2005","unstructured":"Ponce de Le\u00f3n D, Acevedo-V\u00e1squez E, S\u00e1nchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64(9):1360\u20131.","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"417_CR14","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1001\/jama.293.22.2785","volume":"293","author":"CC Whalen","year":"2005","unstructured":"Whalen CC. Diagnosis of latent tuberculosis infection: measure for measure. JAMA. 2005;293(22):2785\u20137.","journal-title":"JAMA"},{"issue":"10","key":"417_CR15","first-page":"1127","volume":"10","author":"L Sichletidis","year":"2006","unstructured":"Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10(10):1127\u201332.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"11","key":"417_CR16","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00296-009-1170-6","volume":"30","author":"T Cagatay","year":"2010","unstructured":"Cagatay T, Aydin M, Sunmez S, et al. Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2010;30(11):1459\u201363.","journal-title":"Rheumatol Int"},{"issue":"9","key":"417_CR17","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00296-011-2017-5","volume":"32","author":"CA Nobre","year":"2012","unstructured":"Nobre CA, Callado MR, Lima JR, Gomes KW, Martiniano GV, Vieira WP. Tuberculosis infection in rheumatic patients with infliximab therapy: experience with 157 patients. Rheumatol Int. 2012;32(9):2769\u201375.","journal-title":"Rheumatol Int"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0417-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-013-0417-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-013-0417-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T21:53:34Z","timestamp":1559080414000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-013-0417-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,6]]},"references-count":17,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["417"],"URL":"https:\/\/doi.org\/10.1007\/s00508-013-0417-0","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,6]]}}}